logo
Plus   Neg
Share
Email

Novartis To Initiate Proof Of Concept Study With Cosentyx - Quick Facts

Novartis (NVS) announced the plan to initiate ARROW, a head-to-head proof of concept study to assess the mechanistic superiority of the direct inhibition of IL-17A with Cosentyx (secukinumab) over the inhibition of IL-23 with Tremfya (guselkumab) in patients with psoriatic plaques resistant to treatment with Stelara. Study results are expected in 2019.

Cosentyx is the first fully-human biologic that specifically inhibits interleukin-17A (IL-17A), a cornerstone cytokine involved in the inflammation and development of psoriasis, ankylosing spondylitis, and psoriatic arthritis.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Zynga Inc. (ZNGA), a social game developer, Tuesday said it has inked a multi-year deal with Disney to develop and publish a new "Star Wars" mobile game. Shares of Zynga is currently up nearly 8 percent, following the news. As a part of the agreement, Zynga will also assume operation of the live service... Furniture maker La-Z-Boy Inc. (LZB), Tuesday reported a profit and revenues for the first quarter that trounced Wall Street estimates, sending its shares surgtin about 20 percent in after-hours trade. Monroe, Michigan-based La-Z-Boy's first-quarter profit rose to $18.3 million or $0.39 per share from... Shares of Keysight Technologies Inc. (KEYS) are up 12 percent on extended session on Tuesday after the company's earnings and revenues for the third quarter trumped Wall Street expectations and outlook for the current quarter also exceeded estimates. Santa Rosa, California-based Keysight Technologies...
Follow RTT